The Readout

By  Damian Garde

Your guide to what’s new in biotech. Sign up for the newsletter here.

The READOUT
The Readout

Biogen’s polarizing data & Veritas’s ‘unexpected’ misfortune

By Damian Garde

The READOUT
The Readout

Sage’s depression drug misses the mark & Lilly’s $8 billion recruitment plan

By Damian Garde

The READOUT
The Readout

Hope and resignation in Huntington’s & the fractured debate on drug pricing

By Damian Garde

The READOUT
The Readout

Astellas buys Audentes & the long odds of ‘Cures 2.0’

By Damian Garde

The READOUT
The Readout

China’s NRDL is out & casting doubt on cardiovascular stem cell therapy

By Meghana Keshavan

The READOUT
The Readout

Biotech’s stunning resurgence & the ease of health tech fraud

By Damian Garde

The READOUT
The Readout

A sickle cell approval & pricing Bluebird’s gene therapies

By Meghana Keshavan

The READOUT
The Readout

Novartis drops $9.7B & Gilead’s PrEP trial

By Meghana Keshavan

The READOUT
The Readout

Biogen’s Al Sandrock speaks & AI’s rapid bio-ascent

By Meghana Keshavan

The READOUT
The Readout

Getting real with Gilead’s CEO & a new RNAi approval

By Meghana Keshavan

The READOUT
The Readout

A CAR-T cottage industry & biotech bankruptcies

By Damian Garde

The READOUT
The Readout

CRISPR in the clinic & what $100 million gets you these days

By Damian Garde

The READOUT
The Readout

A mid-phase schizophrenia success & a sickle cell approval

By Meghana Keshavan

The READOUT
The Readout

Amarin’s victory & whiplash for an ex-unicorn

By Damian Garde

The READOUT
The Readout

Arrowhead’s strange fortune, & the case against AMAG

By Damian Garde

The READOUT
The Readout

Positive signs for Amarin & a Solid setback

By Meghana Keshavan

The Readout

Biotech considers ‘nuclear winter,’ Biogen’s bull case, & $1 billion between friends

By Damian Garde

The READOUT
The Readout

FDA revokes an orphan status & APOE’s Alzheimer’s link grows

By Meghana Keshavan

The READOUT
The Readout

HHS vs. Gilead & more money for pig parts

By Meghana Keshavan

The READOUT
The Readout

Celgene’s CAR-T caveats & Hahn’s path to the FDA

By Damian Garde

The READOUT
The Readout

Myriad’s dominance dwindles & Regeneron pleases the Street

By Damian Garde

The READOUT
The Readout

Biogen’s next FDA hurdle & Sarepta’s state of affairs

By Damian Garde

The READOUT
The Readout

Halozyme’s clinical trial failure & seeking bipartisan pricing policy

By Meghana Keshavan

The READOUT
The Readout

Amgen buys into BeiGene & why antibiotic vouchers may not work

By Meghana Keshavan

The READOUT
The Readout

Biotech’s cliquishness & awkward terms with the FDA

By Damian Garde

The READOUT
The Readout

The next big push in CF & more FDA modernization

By Damian Garde

The READOUT
The Readout

Mirati makes news & a biotech rainmaker returns

By Damian Garde

The READOUT
The Readout

Sacrificing innovation for price & a compelling AI preprint

By Meghana Keshavan

The READOUT
The Readout

A gene therapy turnaround & Cel-Sci’s dualism

By Damian Garde

Your daily dose of news in health and medicine

Privacy Policy